Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants

다국어 초록 (Multilingual Abstract)

Purpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, InfanrixTM IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV).
Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-dose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post vaccination for measurement of immune responses. Reactogenicity was assessed following each dose using diary cards.
Results : One month post-dose 3, seroprotection rates for anti-diphtheria, anti-tetanus and anti-poliovirus types 1, 2 and 3 were ≥99.5% and vaccine response rates to pertussis antigens were at least 98.6% in both DTPa-IPV and DTPa + IPV groups. Non-inferiority between the groups was demonstrated based on pre-defined statistical criteria. Incidences of both local and systemic symptoms were within the same range across both groups with grade 3 symptoms reported following no more than 4.3% of DTPa-IPV doses and 4.5% of DTPa + IPV doses. Two serious adverse events (both pyrexia) after DTPa-IPV administration were considered vaccine-related. Both infants recovered fully.
Conclusion : Combined DTPa-IPV vaccine was immunogenic and well tolerated when used as a three-dose primary vaccination course in Korean infants. DTPa-IPV could be incorporated into the Korean vaccination schedule, reducing the number of injections required to complete primary immunization.

참고문헌 (Reference)

1 강진한, "우리나라 영아에서 3가 정제 백일해 항원 DTaP 백신의면역원성 및 안전성" 대한소아과학회 50 (50): 355-362, 2007

2 유신, "소아 백일해 감염의 유행 및 임상 양상(2000. 3-2001. 3)" 대한소아과학회 45 (45): 7-608, 2002

3 World Health Organization (WHO), "procedure for determining immunity to poliovirus using the microneutralization test"

4 Sun Jun Kim, "Vaccine-associated Paralytic Poliomyelitis: A Case Report of Flaccid Monoparesis after Oral Polio Vaccine" 대한의학회 22 (22): 362-364, 2007

5 Kalies H, "The use of combination vaccines has improved timeliness of vaccination in children" 25 : 507-512, 2006

6 Jefferson T, "Systematic review of the effects of pertussis vaccines in children" 21 : 2003-2014, 2003

7 Lin TY, "Safety and immunogenicity of a diphtheria, tetanus and acellular-pertussis-inactivated poliovirus vaccine/Heamophilus influenza type b combination vaccine administered to Taiwanese infants at 2, 4 and 6 months of age" 26 : 315-322, 2003

8 Jacquet JM, "Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review" 24 : 2440-2448, 2006

9 Schmitt HJ, "Primary vaccination of infants with diphtheria- tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections" 137 : 304-312, 2000

10 World Health Organization (WHO), "Major milestone reached in global polio eradication: Western Pacific region is certified polio-free. Press release WHO/71 29 October 2000"

11 "Korea Centers for Disease Control and Prevention"

12 Weston WM, "Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years" 7 : 1309-1320, 2008

13 Kim HH, "Investigation on the immunity to pertussis in Korea" 34 : 583-589, 1999

14 Immunisation Advisory Centre, "Introducing InfanrixⓇ- hexa fact sheet for parents and caregivers"

15 Camargo ME, "Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum" 20 : 772-774, 1984

16 World Health Organization (WHO), "Immunization surveillance, assessment and monitoring. Immunization Profile - Republic of Korea"

17 Black S, "GlaxoSmith- Kline DTaP-IPV Vaccine Study Group. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years" 24 : 6163-6171, 2006

18 Schmitt HJ, "Efficacy of acellular pertussis vaccine in early childhood after household exposure" 275 : 37-41, 1996

19 "Division of Vaccine Preventable Disease Control and National Immunization Program" 5 : 28-, 2007

20 Black S, "Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age" 27 : 341-346, 2008

21 The Korean Pediatric Society, "DTaP and Td vaccines. In: Immunization Guideline. 6th edition" The Korean Pediatric Society 2008

22 Shek LP, "Comparative study of the reactogenicity of a threecomponent acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants" 34 : 863-868, 2003

23 Begue PC, "Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussisinactivated poliovirus vaccine and diphtheria-tetanusinactivated poliovirus vaccine in preadolescents" 17 : 804-809, 1998

24 Happe LE, "Combination vaccine use and vaccination quality in a managed care population" 13 : 506-512, 2007

25 Pace D, "A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants" 26 : 1057-1059, 2007

26 Nilsson L, "A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age" 37 : 221-229, 2005

27 Greco D, "A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis" 334 : 341-348, 1996

28 Melville-Smith ME, "A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera" 11 : 137-144, 1983

29 Marshall H, "A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years" 24 : 6120-6128, 2006